Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Ann Nutr Metab ; 58(2): 133-40, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21540583

RESUMO

BACKGROUND: Hyperlipidemia and obesity are associated with metabolic syndrome and increased risk in developing diabetes and cardiovascular disease. Nutritional supplements, e.g. L-carnitine and polyunsaturated fatty acids (PUFAs), exert lipid-lowering effects. Hence, the hypothesis that dietetic intervention reduces plasma lipid levels and metabolic enzymes in overweight hyperlipidemic subjects was tested. SUBJECTS AND METHODS: In a prospective placebo-controlled double-blind study in 22 moderately hyperlipidemic obese humans consuming low-fat yoghurt enriched with a combination of low-dose PUFAs, polyphenols and L-carnitine (PPC) twice a day for 12 weeks were compared to 20 matching participants ingesting low-fat yoghurt. The effects on plasma lipids and expression of enzymes involved in regulation of fatty acid oxidation in peripheral blood mononuclear cells (PBMCs) and HepG2 cells were evaluated. RESULTS: PPC consumption led to significantly reduced plasma free fatty acid (-29%) and triglyceride (-24%) concentrations (each p < 0.05). PPC application increased significantly peroxisome proliferator-activated receptor α (PPARα) mRNA abundances and those of PPARα target genes (carnitine palmitoyltransferases-1, CPT1A and CPT1B, carnitine acetyltransferase and organic cation transporter 2; each p < 0.05) in PBMCs. In controls, plasma lipid levels and PBMC gene expression did not change. These findings were substantiated by the results of cell culture experiments in HepG2 cells. CONCLUSION: Supplementation of PPC had marked lipid-lowering effects and PBMC gene expression profiles seemed to reflect nutrition-related metabolic changes.


Assuntos
Carnitina/uso terapêutico , Ácidos Graxos Ômega-3/uso terapêutico , Ácidos Graxos/metabolismo , Flavonoides/uso terapêutico , Leucócitos Mononucleares/metabolismo , Lipídeos/sangue , Fenóis/uso terapêutico , Regulação para Cima , Adulto , Carnitina/administração & dosagem , Carnitina/metabolismo , Método Duplo-Cego , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/metabolismo , Feminino , Flavonoides/administração & dosagem , Flavonoides/metabolismo , Alimento Funcional/análise , Células Hep G2 , Hepatócitos/metabolismo , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/dietoterapia , Hiperlipidemias/metabolismo , Hipolipemiantes/administração & dosagem , Hipolipemiantes/metabolismo , Masculino , Pessoa de Meia-Idade , Sobrepeso/complicações , Oxirredução , PPAR alfa/genética , PPAR alfa/metabolismo , Fenóis/administração & dosagem , Fenóis/metabolismo , Polifenóis , RNA Mensageiro/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA